## UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

## Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2017

PRESTIGE BRANDS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)

## Delaware

(State or other jurisdiction of incorporation)

001-32433
(Commission File Number)

660 White Plains Road, Tarrytown, New York 10591 (Address of principal executive offices, including Zip Code)

## (914) 524-6800

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 chapter).
Emerging Growth Company
 the Exchange Act. o

On May 11, 2017, Prestige Brands Holdings, Inc. (the "Company") announced financial results for the fiscal quarter and year ended March 31, 2017. A copy of the press release announcing the Company's earnings results for the fiscal quarter and year ended March 31, 2017 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

## Item 7.01. Regulation FD Disclosure.

The information set forth in Item 2.02 above is incorporated by reference as if fully set forth herein.

 analysts and others during the fiscal year ended March 31, 2018.
 of Regulation FD.

The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public
 from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

 filing under the Securities Act of 1933, as amended, or the Exchange Act.

## Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

See Exhibit Index immediately following the signature page.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PRESTIGE BRANDS HOLDINGS, INC.

By: /s/ Christine Sacco
Name: Christine Sacco
Title: Chief Financial Officer

Press Release dated May 11, 2017 announcing the Company's financial results for the fiscal quarter and year ended March 31, 2017 (furnished only).
Investor Relations Slideshow in use beginning May 11, 2017 (furnished only).

## Prestige Brands Holdings, Inc. Reports Fiscal 2017 Fourth Quarter and Full Year Results; Provides Fiscal 2018 Outlook

- Reported revenue increased $15.8 \%$ to $\$ 240.7$ million and $9.4 \%$ to $\$ 882.1$ million in Q4 and fiscal 2017, respectively.
- Generated $\$ 147.8$ million in fiscal 2017 GAAP net cash provided by operating activities and adjusted non-GAAP free cash flow of $\$ 196.0$ million.
- Anticipate 18 to $20 \%$ revenue growth in fiscal 2018.
- Fiscal 2018 GAAP EPS guidance of \$2.50 to 2.60; Non-GAAP Adjusted EPS outlook of \$2.58-2.68.
- C.B. Fleet acquisition successfully closed January $26^{\text {th }}$; integration and cost savings efforts tracking as anticipated.

TARRYTOWN, N.Y.--(BUSINESS WIRE)--May 11, 2017-- Prestige Brands Holdings, Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2017.
"Our solid overall fourth quarter performance was broad-based, benefitting from our diverse product offering, ongoing brand-building investments, and the strategic evolution of our portfolio throughout the fiscal year. Equally
 fiscal 2018," said Ron Lombardi, Chief Executive Officer of Prestige Brands.

## Fiscal Fourth Quarter Ended March 31, 2017



 non-GAAP organic revenue growth increased $1.1 \%$ versus the prior year comparable quarter.

 Non-GAAP adjusted earnings per share were $\$ 0.54$ per share for the fourth quarter of fiscal 2017, compared to $\$ 0.52$ per share in the prior year comparable period.
 debt, and the related income tax effects of the adjustments.

## Fiscal Year Ended March 31, 2017

 organic revenues (a non-GAAP measure) for the fiscal year ended March 31, 2017 increased 1.0\%.
 2017 totaled $\$ 126.6$ million, or $\$ 2.37$ per diluted share, an increase of $9.6 \%$ compared to adjusted net income of $\$ 115.5$ million, or $\$ 2.17$ per diluted share, for fiscal 2016 .

Adjustments to net income in fiscal 2017 include integration, transition, purchase accounting, legal and various other costs associated with acquisitions and divestitures, a loss on extinguishment of debt, a net loss related to the
 with acquisitions and divestitures, as well as costs associated with CEO transition.

## Free Cash Flow and Balance Sheet

 as income tax payments resulting from divestitures. Non-GAAP adjusted free cash flow for the fourth fiscal quarter was $\$ 46.8$ million, down from $\$ 48.7$ million in the prior year comparable quarter.
 $\$ 183.4$ million in the prior year's period.
 leverage ratio was approximately 5.7 x , supported by the Company's consistent and industry-leading free cash flow. The company expects to reach an approximate 5.0 x covenant-defined leverage ratio by the end of fiscal 2018 .

## Segment Review


 consumption among the majority of core OTC brands as well as revenues from the acquisitions of DenTek and Fleet, partially offset by divestitures of non-core OTC brands.

 DenTek and Fleet transactions.
 $\$ 87.9$ million, a $3.0 \%$ decrease over fiscal year 2016 revenues of $\$ 90.7$ million.

## Commentary and Outlook for Fiscal 2018


 been our practice, we plan to continue using our industry-leading free cash flow to pay down debt and build M\&A capacity," he stated.
 prospects surrounding both our legacy portfolio and the recent acquisition of Fleet," Mr. Lombardi concluded.

## Fiscal 2018 Full-Year Outlook


 high standards of performance throughout our organization. The Board is confident he will provide outstanding leadership as Chairman, President and CEO in the coming years."

## Q4 and Fiscal Year Conference Call, Accompanying Slide Presentation and Replay



 available for two weeks following the completion of the call and can be accessed at 855-859-2056 within North America and at 404-537-3406 from outside North America. The conference ID is 6720925.

## Non-GAAP Financial Information

 performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the "About Non-GAAP Financial Measures" section at the end of this earnings release.

## Note Regarding Forward-Looking Statements








 in the Company's Annual Report on Form 10-K for the year ended March 31, 2016, Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, and other periodic reports filed with the Securities and Exchange Commission.

## About Prestige Brands Holdings, Inc.



 remover, Gaviscon® antacid in Canada, and

## Prestige Brands Holdings, Inc.

| (In thousands, except per share data). | Three Months Ended March 31, |  |  |  | Year Ended March 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| Revenues |  |  |  |  |  |  |  |  |
| Net sales | \$ | 240,594 | \$ | 207,054 | \$ | 881,113 | \$ | 803,088 |
| Other revenues |  | 76 |  | 801 |  | 947 |  | 3,159 |
| Total revenues |  | 240,670 |  | 207,855 |  | 882,060 |  | 806,247 |
| Cost of Sales |  |  |  |  |  |  |  |  |
| Cost of sales |  | 110,487 |  | 89,604 |  | 381,774 |  | 339,036 |
| Gross profit |  | 130,183 |  | 118,251 |  | 500,286 |  | 467,211 |
| Operating Expenses |  |  |  |  |  |  |  |  |
| Advertising and promotion |  | 41,450 |  | 26,552 |  | 128,359 |  | 110,802 |
| General and administrative |  | 28,760 |  | 20,232 |  | 89,143 |  | 72,418 |
| Depreciation and amortization |  | 6,651 |  | 6,198 |  | 25,351 |  | 23,676 |
| Loss on divestitures |  | 268 |  | - |  | 51,820 |  | - |
| Total operating expenses |  | 77,129 |  | 52,982 |  | 294,673 |  | 206,896 |
| Operating income |  | 53,054 |  | 65,269 |  | 205,613 |  | 260,315 |
| Other (income) expense |  |  |  |  |  |  |  |  |
| Interest income |  | (54) |  | (71) |  | (203) |  | (162) |
| Interest expense |  | 32,886 |  | 23,218 |  | 93,546 |  | 85,322 |
| Loss on extinguishment of debt |  | 1,420 |  | 17,519 |  | 1,420 |  | 17,970 |
| Total other expense |  | 34,252 |  | 40,666 |  | 94,763 |  | 103,130 |
| Income before income taxes |  | 18,802 |  | 24,603 |  | 110,850 |  | 157,185 |
| Provision for income taxes |  | 7,712 |  | 10,667 |  | 41,455 |  | 57,278 |
| Net income | \$ | 11,090 | \$ | 13,936 | \$ | 69,395 | \$ | 99,907 |
| Earnings per share: |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| Basic | \$ | 0.21 | \$ | 0.26 | \$ | 1.31 | \$ | 1.89 |
| Diluted | \$ | 0.21 | \$ | 0.26 | \$ | 1.30 | \$ | 1.88 |
| Weighted average shares outstanding: |  |  |  |  |  |  |  |  |
| Basic |  | 53,009 |  | 52,833 |  | 52,976 |  | 52,754 |
| Diluted |  | 53,419 |  | 53,252 |  | 53,362 |  | 53,143 |
|  |  |  |  |  |  |  |  |  |
| Comprehensive income, net of tax: |  |  |  |  |  |  |  |  |
| Currency translation adjustments |  | 9,282 |  | 6,449 |  | $(2,575)$ |  | (113) |
| Pension liability |  | (252) |  | - |  | (252) |  | - |
| Total other comprehensive income (loss) |  | 9,030 |  | 6,449 |  | $(2,827)$ |  | (113) |
| Comprehensive income | \$ | 20,120 | \$ | 20,385 | \$ | 66,568 | \$ | 99,794 |

## Prestige Brands Holdings, Inc.

 Consolidated Balance Sheet (Unaudited)

## Prestige Brands Holdings, Inc

## Consolidated Statement of Cash Flows

 (Unaudited)| (In thousands). | Year Ended March 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  |
| Operating Activities |  |  |  |  |
| Net income | \$ | 69,395 | \$ | 99,907 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |  |
| Depreciation and amortization |  | 25,792 |  | 23,676 |
| Loss on divestitures and sales of property and equipment |  | 51,820 |  | - |
| Deferred income taxes |  | $(5,778)$ |  | 46,152 |
| Long term income taxes payable |  | 581 |  | (332) |
| Amortization of debt origination costs |  | 8,633 |  | 8,994 |
| Stock-based compensation costs |  | 8,148 |  | 9,954 |
| Loss on extinguishment of debt |  | 1,420 |  | 17,970 |
| Premium payment on 2012 Senior Notes |  | - |  | $(10,158)$ |
| Lease termination costs |  | 524 |  | - |
| Loss (gain) on sale or disposal of property and equipment |  | 573 |  | (35) |
| Changes in operating assets and liabilities, net of effects from acquisitions |  |  |  |  |
| Accounts receivable |  | $(18,938)$ |  | 1,824 |
| Inventories |  | $(10,262)$ |  | $(3,005)$ |
| Prepaid expenses and other assets |  | $(1,996)$ |  | $(7,921)$ |
| Accounts payable |  | 21,447 |  | $(11,348)$ |
| Accrued liabilities |  | 2,497 |  | $(1,328)$ |
| Noncurrent assets and liabilities |  | $(6,084)$ |  | - |
| Net cash provided by operating activities |  | 147,772 |  | 174,350 |
| Investing Activities |  |  |  |  |
| Purchases of property and equipment |  | $(2,977)$ |  | $(3,568)$ |
| Proceeds from divestitures |  | 110,717 |  | - |
| Proceeds from the sale of property and equipment |  | 85 |  | 344 |
| Proceeds from Insight Pharmaceuticals working capital arbitration settlement |  | - |  | 7,237 |
| Proceeds from DenTek working capital arbitration settlement |  | 1,419 |  | - |
| Acquisition of DenTek, less cash acquired |  | - |  | $(226,984)$ |
| Acquisition of C.B. Fleet, less cash acquired |  | $(803,839)$ |  | - |
| Net cash used in investing activities |  | $(694,595)$ |  | $(222,971)$ |
| Financing Activities |  |  |  |  |
| Proceeds from issuance of 2016 Senior Notes |  | - |  | 350,000 |
| Repayment of 2012 Senior Notes |  | - |  | $(250,000)$ |
| Borrowings under Bridge term loans |  | - |  | 80,000 |
| Repayments under Bridge term loans |  | - |  | $(80,000)$ |
| Proceeds from issuance of Term Loan |  | 1,427,000 |  | - |
| Term Loan repayments resulting from refinancing |  | $(687,000)$ |  | - |
| Term Loan repayments |  | $(175,500)$ |  | $(60,000)$ |
| Borrowings under revolving credit agreement |  | 110,000 |  | 115,000 |
| Repayments under revolving credit agreement |  | $(105,000)$ |  | $(96,100)$ |
| Payments of debt origination costs |  | $(11,140)$ |  | $(11,828)$ |
| Proceeds from exercise of stock options |  | 4,028 |  | 6,689 |
| Proceeds from restricted stock exercises |  | - |  | 544 |
| Excess tax benefits from share-based awards |  | 900 |  | 1,960 |
| Fair value of shares surrendered as payment of tax withholding |  | $(1,431)$ |  | $(2,229)$ |
| Net cash provided by financing activities |  | 561,857 |  | 54,036 |
| Effects of exchange rate changes on cash and cash equivalents |  | (409) |  | 497 |
| Increase in cash and cash equivalents |  | 14,625 |  | 5,912 |
| Cash and cash equivalents - beginning of year |  | 27,230 |  | 21,318 |
| Cash and cash equivalents - end of year | \$ | 41,855 | \$ | 27,230 |
|  |  |  |  |  |
| Interest paid | \$ | 85,209 | \$ | 79,132 |
| Income taxes paid | \$ | 47,999 | \$ | 15,352 |

Prestige Brands Holdings, Inc.

| (In thousands). | Three Months Ended March 31, 2017 |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated |  |
| Gross segment revenues | \$ | 201,003 | \$ | 20,226 | \$ | 21,377 | \$ | 242,606 |
| Elimination of intersegment revenues |  | $(2,012)$ |  | - |  | - |  | $(2,012)$ |
| Third-party segment revenues |  | 198,991 |  | 20,226 |  | 21,377 |  | 240,594 |
| Other revenues |  | 33 |  | 11 |  | 32 |  | 76 |
| Total segment revenues |  | 199,024 |  | 20,237 |  | 21,409 |  | 240,670 |
| Cost of sales |  | 84,736 |  | 9,067 |  | 16,684 |  | 110,487 |
| Gross profit |  | 114,288 |  | 11,170 |  | 4,725 |  | 130,183 |
| Advertising and promotion |  | 35,814 |  | 4,564 |  | 1,072 |  | 41,450 |
| Contribution margin | \$ | 78,474 | \$ | 6,606 | \$ | 3,653 | \$ | 88,733 |
| Other operating expenses |  |  |  |  |  |  |  | 35,679 |
| Operating income |  |  |  |  |  |  |  | 53,054 |
| Other expense |  |  |  |  |  |  |  | 34,252 |
| Income before income taxes |  |  |  |  |  |  |  | 18,802 |
| Provision for income taxes |  |  |  |  |  |  |  | 7,712 |
| Net income |  |  |  |  |  |  | \$ | 11,090 |


| (In thousands). | Year Ended March 31, 2017 |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated |  |
| Gross segment revenues | \$ | 724,991 | \$ | 73,287 | \$ | 87,035 | \$ | 885,313 |
| Elimination of intersegment revenues |  | $(4,200)$ |  | - |  | - |  | $(4,200)$ |
| Third-party segment revenues |  | 720,791 |  | 73,287 |  | 87,035 |  | 881,113 |
| Other revenues |  | 33 |  | 17 |  | 897 |  | 947 |
| Total segment revenues |  | 720,824 |  | 73,304 |  | 87,932 |  | 882,060 |
| Cost of sales |  | 282,750 |  | 30,789 |  | 68,235 |  | 381,774 |
| Gross profit |  | 438,074 |  | 42,515 |  | 19,697 |  | 500,286 |
| Advertising and promotion |  | 112,465 |  | 13,434 |  | 2,460 |  | 128,359 |
| Contribution margin | \$ | 325,609 | \$ | 29,081 | \$ | 17,237 | \$ | 371,927 |
| Other operating expenses* |  |  |  |  |  |  |  | 166,314 |
| Operating income |  |  |  |  |  |  |  | 205,613 |
| Other expense |  |  |  |  |  |  |  | 94,763 |
| Income before income taxes |  |  |  |  |  |  |  | 110,850 |
| Provision for income taxes |  |  |  |  |  |  |  | 41,455 |
| Net income |  |  |  |  |  |  | \$ | 69,395 |


 are included in the Household Cleaning segment.

Three Months Ended March 31, 2016

| (In thousands). | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Gross segment revenues | \$ | 171,253 | \$ | 14,457 | \$ | 21,577 | \$ | 207,287 |
| Elimination of intersegment revenues |  | (233) |  | - |  | - |  | (233) |
| Third-party segment revenues |  | 171,020 |  | 14,457 |  | 21,577 |  | 207,054 |
| Other revenues |  | (1) |  | 3 |  | 799 |  | 801 |
| Total segment revenues |  | 171,019 |  | 14,460 |  | 22,376 |  | 207,855 |
| Cost of sales |  | 67,739 |  | 5,329 |  | 16,536 |  | 89,604 |
| Gross profit |  | 103,280 |  | 9,131 |  | 5,840 |  | 118,251 |
| Advertising and promotion |  | 23,286 |  | 2,776 |  | 490 |  | 26,552 |
| Contribution margin | \$ | 79,994 | \$ | 6,355 | \$ | 5,350 | \$ | 91,699 |
| Other operating expenses |  |  |  |  |  |  |  | 26,430 |
| Operating income |  |  |  |  |  |  |  | 65,269 |
| Other expense |  |  |  |  |  |  |  | 40,666 |
| Income before income taxes |  |  |  |  |  |  |  | 24,603 |
| Provision for income taxes |  |  |  |  |  |  |  | 10,667 |
| Net income |  |  |  |  |  |  | \$ | 13,936 |


| (In thousands). |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | North American OTC Healthcare |  | International OTC Healthcare |  | Household Cleaning |  | Consolidated |  |
| Gross segment revenues | \$ | 660,518 | \$ | 57,670 | \$ | 87,561 | \$ | 805,749 |
| Elimination of intersegment revenues |  | $(2,661)$ |  | - |  | - |  | $(2,661)$ |
| Third-party segment revenues |  | 657,857 |  | 57,670 |  | 87,561 |  | 803,088 |
| Other revenues |  | 14 |  | 43 |  | 3,102 |  | 3,159 |
| Total segment revenues |  | 657,871 |  | 57,713 |  | 90,663 |  | 806,247 |
| Cost of sales |  | 250,018 |  | 21,676 |  | 67,342 |  | 339,036 |
| Gross profit |  | 407,853 |  | 36,037 |  | 23,321 |  | 467,211 |
| Advertising and promotion |  | 97,393 |  | 11,114 |  | 2,295 |  | 110,802 |
| Contribution margin | \$ | 310,460 | \$ | 24,923 | \$ | 21,026 | \$ | 356,409 |
| Other operating expenses |  |  |  |  |  |  |  | 96,094 |
| Operating income |  |  |  |  |  |  |  | 260,315 |
| Other expense |  |  |  |  |  |  |  | 103,130 |
| Income before income taxes |  |  |  |  |  |  |  | 157,185 |
| Provision for income taxes |  |  |  |  |  |  |  | 57,278 |
| Net income |  |  |  |  |  |  | \$ | 99,907 |

## About Non-GAAP Financial Measures








 the performance of our personnel and also to evaluate our operating performance and compare our performance to that of our competitors.


 and a more complete understanding of factors affecting our business than GAAP measures alone.

## NGFMs Defined

We define our NGFMs presented herein as follows:

- Non-GAAP Organic Revenues: GAAP Total Revenues excluding revenues associated with products acquired or divested in the periods presented.
- Non-GAAP Adjusted Gross Margin: GAAP Gross Profit minus inventory set-up charges and certain integration, transition and other acquisition related costs.
- Non-GAAP Adjusted Gross Margin Percentage: Calculated as Non-GAAP Adjusted Gross Margin divided by GAAP Total Revenues
- Non-GAAP Adjusted Advertising and Promotion Expense: GAAP Advertising and Promotion expenses minus certain integration, transition and other acquisition related costs.
- Non-GAAP Adjusted Advertising and Promotion Expense Percentage: Calculated as Non-GAAP Adjusted Advertising and Promotion expense divided by GAAP Total Revenues.
 and costs associated with our CEO transition.
- Non-GAAP Adjusted General and Administrative Expense Percentage: Calculated as Non-GAAP Adjusted General and Administrative expense divided by GAAP Total Revenues.
- Non-GAAP EBITDA: GAAP Net Income less interest expense (income), income taxes, and depreciation and amortization.
- Non-GAAP EBITDA Margin: Calculated as Non-GAAP EBITDA divided by GAAP Total Revenues.
 CEO transition, loss on extinguishment of debt, and gain/loss on divestitures.
- Non-GAAP Adjusted EBITDA Margin: Calculated as Non-GAAP Adjusted EBITDA divided by GAAP Total Revenues.
 accelerated amortization
 adjustments and other non-deductible items.
- Non-GAAP Adjusted EPS: Calculated as Non-GAAP Adjusted Net Income, divided by the weighted average number of common and potential common shares outstanding during the period.
- Non-GAAP Free Cash Flow: GAAP Net cash provided by operating activities less cash paid for capital expenditures.
 Senior Notes, additional interest expense on debt refinancing, pension obligation funding and additional income tax payments associated with divestitures.

The following tables set forth the reconciliations of each of our NGFMs to their most directly comparable financial measures presented in accordance with GAAP.

## Reconciliation of GAAP Total Revenues to Non-GAAP Organic Revenues and related growth percentages:

|  | Three Months Ended March 31, |  |  |  | Year Ended <br> March 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| (In thousands). |  |  |  |  |  |  |  |  |
| GAAP Total Revenues | \$ | 240,670 | \$ | 207,855 | \$ | 882,060 | \$ | 806,247 |
| Revenue Growth |  | $\underline{ }$ |  |  |  | 9.4\% |  |  |
| Adjustments: |  |  |  |  |  |  |  |  |
| Revenues associated with acquisitions ${ }^{(1)}$ |  | $(43,125)$ |  | - |  | $(94,293)$ |  | - |
| Revenues associated with divested brands ${ }^{(2)}$ |  | - |  | $(12,460)$ |  | - |  | $(26,002)$ |
| Total adjustments |  | $(43,125)$ |  | $(12,460)$ |  | $(94,293)$ |  | $(26,002)$ |
| Non-GAAP Organic Revenues | \$ | 197,545 | \$ | 195,395 | \$ | 787,767 | \$ | 780,245 |
| Organic Revenue Growth |  | 1.1\% |  |  |  | 1.0\% |  |  |

(1) Revenues of our acquisitions, Fleet and DenTek, are excluded for purposes of calculating Non-GAAP organic revenues. These revenue adjustments relate to our North American and International OTC Healthcare segments.
(2) Revenues of our divested brands have been excluded from the current year and the prior year for purposes of calculating Non-GAAP organic revenues. These revenue adjustments relate to our North American OTC Healthcare segment and our Household Cleaning segment.

## Reconciliation of GAAP Gross Profit to Non-GAAP Adjusted Gross Margin and related Adjusted Gross Margin percentage:

|  | Three Months Ended March 31, |  |  |  | Year Ended March 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| (In thousands). |  |  |  |  |  |  |  |  |
| GAAP Total Revenues | \$ | 240,670 | \$ | 207,855 | \$ | 882,060 | \$ | 806,247 |
|  |  |  |  |  |  |  |  |  |
| GAAP Gross Profit | \$ | 130,183 | \$ | 118,251 | \$ | 500,286 | \$ | 467,211 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Inventory step-up charges and other costs associated with acquisitions ${ }^{(1)}$ |  | 1,664 |  | 1,387 |  | 1,664 |  | 1,387 |
| Integration, transition and other costs associated with acquisitions |  | 1,367 |  | - |  | 1,367 |  | - |
| Total adjustments |  | 3,031 |  | 1,387 |  | 3,031 |  | 1,387 |
| Non-GAAP Adjusted Gross Margin | \$ | 133,214 | \$ | 119,638 | \$ | 503,317 | \$ | 468,598 |
| Non-GAAP Adjusted Gross Margin \% |  | 55.4\% |  | 57.6\% |  | 57.1\% |  | 58.1\% |


|  | Three Months Ended March 31, |  |  |  | Year Ended March 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| (In thousands). |  |  |  |  |  |  |  |  |
| GAAP Advertising and Promotion Expense | \$ | 41,450 | \$ | 26,552 | \$ | 128,359 | \$ | 110,802 |
| GAAP Advertising and Promotion Expense as a Percentage of GAAP Total Revenue |  | 17.2\% |  | 12.8\% |  | 14.6\% |  | 13.7\% |
| Adjustments: |  |  |  |  |  |  |  |  |
| Integration, transition and other costs associated with acquisitions ${ }^{(1)}$ |  | 2,242 |  | - |  | 2,242 |  | - |
| Total adjustments |  | 2,242 |  | - |  | 2,242 |  | - |
| Non-GAAP Adjusted Advertising and Promotion Expense | \$ | 39,208 | \$ | 26,552 | \$ | 126,117 | \$ | 110,802 |
| Non-GAAP Adjusted Advertising and Promotion Expense as a Percentage of GAAP Total Revenues |  | 16.3\% |  | 12.8\% |  | 14.3\% |  | 13.7\% |

 Adjusted General and Administrative Expense percentage:

|  | Three Months Ended March 31, |  |  |  | Year Ended March 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| (In thousands). |  |  |  |  |  |  |  |  |
| GAAP General and Administrative Expense | \$ | 28,760 | \$ | 20,232 | \$ | 89,143 | \$ | 72,418 |
| GAAP General and Administrative Expense as a Percentage of GAAP Total Revenue |  | 11.9\% |  | 9.7\% |  | 10.1\% |  | 9.0\% |
| Adjustments: |  |  |  |  |  |  |  |  |
| Costs associated with CEO transition ${ }^{(1)}$ |  | - |  | - |  | - |  | 1,406 |
| Legal and professional fees associated with acquisitions and divestitures ${ }^{(2)}$ |  |  |  |  |  |  |  |  |
|  |  | 3,431 |  | 1,096 |  | 6,560 |  | 2,112 |
| Integration, transition and other costs associated with acquisitions and divestitures ${ }^{(2)}$ |  | 5,756 |  | 289 |  | 9,455 |  | 289 |
| Total adjustments |  | 9,187 |  | 1,385 |  | 16,015 |  | 3,807 |
| Non-GAAP Adjusted General and Administrative Expense | \$ | 19,573 | \$ | 18,847 | \$ | 73,128 | \$ | 68,611 |
| Non-GAAP Adjusted General and Administrative Expense as a Percentage of GAAP Total Revenues |  | 8.1\% |  | 9.1\% |  | 8.3\% |  | 8.5\% |

(1) Costs relate to search fees associated with CEO and CFO transition and certain accelerated stock compensation costs related to our former CEO
 acquisition process such as insurance costs, legal and other acquisition related professional fees.

|  | Three Months Ended March 31, |  |  |  | Year Ended March 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| (In thousands). |  |  |  |  |  |  |  |  |
| GAAP Net Income | \$ | 11,090 | \$ | 13,936 | \$ | 69,395 | \$ | 99,907 |
| Interest expense, net |  | 32,832 |  | 23,147 |  | 93,343 |  | 85,160 |
| Provision for income taxes |  | 7,712 |  | 10,667 |  | 41,455 |  | 57,278 |
| Depreciation and amortization |  | 7,092 |  | 6,198 |  | 25,792 |  | 23,676 |
| Non-GAAP EBITDA |  | 58,726 |  | 53,948 |  | 229,985 |  | 266,021 |
| Non-GAAP EBITDA Margin |  | 24.4\% |  | 26.0\% |  | 26.1\% |  | 33.0\% |
| Adjustments: |  |  |  |  |  |  |  |  |
| Inventory step-up charges and other costs associated with acquisitions ${ }^{(1)}$ |  | 1,664 |  | 1,387 |  | 1,664 |  | 1,387 |
| Integration, transition and other costs associated with acquisitions and divestitures in Cost of Goods Sold ${ }^{(3)}$ |  | 1,367 |  | - |  | 1,367 |  | - |
| Integration, transition and other costs associated with acquisitions and divestitures in Advertising and Promotion Expense ${ }^{(3)}$ |  | 2,242 |  | - |  | 2,242 |  | - |
| Integration, transition and other costs associated with acquisitions and divestitures in General and Administrative Expense ${ }^{(3)}$ |  | 5,756 |  | 289 |  | 9,455 |  | 289 |
| Costs associated with CEO transition ${ }^{(2)}$ |  | - |  | - |  | - |  | 1,406 |
| Legal and professional fees associated with acquisitions and divestitures ${ }^{(3)}$ |  | 3,431 |  | 1,096 |  | 6,560 |  | 2,112 |
| Loss on extinguishment of debt |  | 1,420 |  | 17,519 |  | 1,420 |  | 17,970 |
| (Gain) loss on divestitures |  | 268 |  | - |  | 51,820 |  | - |
| Total adjustments |  | 16,148 |  | 20,291 |  | 74,528 |  | 23,164 |
| Non-GAAP Adjusted EBITDA | \$ | 74,874 | \$ | 74,239 | \$ | 304,513 | \$ | 289,185 |
| Non-GAAP Adjusted EBITDA Margin |  | 31.1\% |  | 35.7\% |  | 34.5\% |  | 35.9\% |

(1) Inventory step-up charges relate to our North American and International OTC Healthcare segments.
(2) Costs relate to search fees associated with CEO and CFO transition and certain accelerated stock compensation costs related to our former CEO,
 acquisition process such as insurance costs, legal and other acquisition related professional fees.

Three Months Ended March 31,
Year Ended March 31,

|  | Months Ended March 31, |  |  |  |  |  |  |  | ar Ende |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2017 AdjustedEPS |  | 2016 |  | 2016 Adjusted EPS |  | 2017 |  | 2017 Adjusted EPS |  | 2016 |  | 2016 Adjusted EPS |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| (In thousands). |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| GAAP Net Income | \$ | 11,090 | \$ | 0.21 | \$ | 13,936 | \$ | 0.26 | \$ | 69,395 | \$ | 1.30 | \$ | 99,907 | \$ | 1.88 |
| Adjustments: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Inventory step-up charges and other costs associated with acquisitions ${ }^{(1)}$ |  | 1,664 |  | 0.03 |  | 1,387 |  | 0.03 |  | 1,664 |  | 0.03 |  | 1,387 |  | 0.03 |
| Integration, transition and other costs associated with acquisitions and divestitures in Cost of Goods Sold ${ }^{(2)}$ |  | 1,367 |  | 0.03 |  | - |  | - |  | 1,367 |  | 0.03 |  | - |  | - |
| Integration, transition and other costs associated with acquisitions and divestitures in Advertising and Promotion Expense ${ }^{(2)}$ |  | 2,242 |  | 0.04 |  | - |  | - |  | 2,242 |  | 0.04 |  | - |  | - |
| Integration, transition and other costs associated with acquisitions and divestitures in General and Administrative Expense ${ }^{(2)}$ |  | 5,756 |  | 0.11 |  | 289 |  | 0.01 |  | 9,455 |  | 0.18 |  | 289 |  | 0.01 |
| Costs associated with CEO transition ${ }^{(3)}$ |  | - |  | - |  | - |  | - |  | - |  | - |  | 1,406 |  | 0.02 |
| Legal and professional fees associated with acquisitions and divestitures ${ }^{(2)}$ |  | 3,431 |  | 0.06 |  | 1,096 |  | 0.02 |  | 6,560 |  | 0.12 |  | 2,112 |  | 0.04 |
| Accelerated amortization of debt origination costs ${ }^{(4)}$ |  | 575 |  | 0.01 |  | - |  | - |  | 1,706 |  | 0.03 |  | - |  | - |
| Additional interest expense as a result of Term Loan debt refinancing ${ }^{\text {(5) }}$ |  | 9,184 |  | 0.17 |  | - |  | - |  | 9,184 |  | 0.17 |  | - |  | - |
| Loss on extinguishment of debt |  | 1,420 |  | 0.03 |  | 17,519 |  | 0.33 |  | 1,420 |  | 0.03 |  | 17,970 |  | 0.34 |
| (Gain) loss on divestitures |  | 268 |  | 0.01 |  | - |  | - |  | 51,820 |  | 0.97 |  | - |  | - |
| Tax impact of adjustments ${ }^{(6)}$ |  | $(9,438)$ |  | (0.18) |  | $(6,294)$ |  | (0.13) |  | $(28,024)$ |  | (0.53) |  | $(7,608)$ |  | (0.15) |
| Income tax related to adjustments ${ }^{(7)}$ |  | 1,278 |  | 0.02 |  | - |  | - |  | (199) |  | - |  | - |  | - |
| Total adjustments |  | 17,747 |  | 0.33 |  | 13,997 |  | 0.26 |  | 57,195 |  | 1.07 |  | 15,556 |  | 0.29 |
| Non-GAAP Adjusted Net Income and Adjusted EPS | \$ | 28,837 | \$ | 0.54 | \$ | 27,933 | \$ | 0.52 | \$ | 126,590 | \$ | 2.37 | \$ | 115,463 | \$ | 2.17 |

(1) Inventory set-up charges relate to our North American and International OTC Healthcare segments.
 acquisition process such as legal and other acquisition related professional fees.
(3) Costs relate to
) Higher amortization of debt oignation costs resulting from debt payments on our term loan from the proceeds from divestitures.
(6) The income tax adjustments are determined using applicable rates in the taxing jurisdictions in which the above adjustments relate and includes both current and deferred income tax expense (benefit) based on the specific nature of the specific Non-GAAP performance measure. (7) Income tax adjustments relate primarily to the expiration of certain statute of limitations associated with certain tax reserves and a normalized tax rate of $35.5 \%$.

## Reconciliation of GAAP Net Income to Non-GAAP Free Cash Flow and Non-GAAP Adjusted Free Cash Flow

|  | Three Months Ended March 31, |  |  |  | Year Ended March 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| (In thousands). |  |  |  |  |  |  |  |  |
| GAAP Net Income | \$ | 11,090 | \$ | 13,936 | \$ | 69,395 | \$ | 99,907 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Adjustments to reconcile net income to net cash provided by operating activities as shown in the Statement of Cash Flows |  | 21,347 |  | 34,206 |  | 91,713 |  | 96,221 |
| Changes in operating assets and liabilities, net of effects from acquisitions as shown in the Statement of Cash Flows |  | $(25,013)$ |  | $(10,243)$ |  | $(13,336)$ |  | $(21,778)$ |
| Total adjustments |  | $(3,666)$ |  | 23,963 |  | 78,377 |  | 74,443 |
| GAAP Net cash provided by operating activities |  | 7,424 |  | 37,899 |  | 147,772 |  | 174,350 |
| Purchases of property and equipment |  | $(1,042)$ |  | $(1,028)$ |  | $(2,977)$ |  | $(3,568)$ |
| Non-GAAP Free Cash Flow |  | 6,382 |  | 36,871 |  | 144,795 |  | 170,782 |
| Premium payment on extinguishment of 2012 Senior Notes |  | - |  | 10,158 |  | - |  | 10,158 |
| Integration, transition and other payments associated with acquisitions and divestitures ${ }^{(1)}$ |  | 8,304 |  | 1,665 |  | 10,448 |  | 2,461 |
| Additional interest on Term Loan refinance ${ }^{(2)}$ |  | 9,184 |  | - |  | 9,184 |  | - |
| Pension contribution |  | 6,000 |  | - |  | 6,000 |  | - |
| Additional income tax payments associated with divestitures ${ }^{(3)}$ |  | 16,956 |  | - |  | 25,545 |  | - |
| Non-GAAP Adjusted Free Cash Flow | \$ | 46,826 | \$ | 48,694 | \$ | 195,972 | \$ | 183,401 |
|  acquisition process such as legal and other acquisition related professional fees. <br> (2) Primarily bank commitment fees related to the recently acquired Fleet business. <br> (3) Additional income tax payments resulting from divestitures. |  |  |  |  |  |  |  |  |

## Outlook for Fiscal Year 2018

Reconciliation of Projected GAAP EPS to Projected Non-GAAP Adjusted EPS:

|  | 2018 Projected EPS |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Low |  | High |  |
| Projected FY'18 GAAP EPS | \$ | 2.50 | \$ | 2.60 |
| Adjustments: |  |  |  |  |
| Costs associated with Fleet integration ${ }^{(1)}$ |  | 0.08 |  | 0.08 |
| Total adjustments |  | 0.08 |  | 0.08 |
| Projected Non-GAAP Adjusted EPS | \$ | 2.58 | \$ | 2.68 |

Reconciliation of Projected GAAP Net cash provided by operating activities to Projected Non-GAAP Adjusted Free Cash Flow:

| (In millions). | 2018 Projected Free Cash Flow |  |
| :---: | :---: | :---: |
|  |  |  |
| Projected FY'18 GAAP Net cash provided by operating activities | \$ | 210 |
| Additions to property and equipment for cash |  | (10) |
| Projected Non-GAAP Free Cash Flow |  | 200 |
| Payments associated with acquisitions ${ }^{(1)}$ |  | 8 |
| Tax effect of payments associated with acquisitions |  | (3) |
| Projected Non-GAAP Adjusted Free Cash Flow | \$ | 205 | consummation of the acquisition process such as legal and other acquisition related professional fees.

## PrestigeBrands

Review of Fourth Quarter and FY 17 Results May 11, 2017


## Safe Harbor Disclosure

This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenue growth, organic growth, adjusted EPS, adjusted free cash flow, and adjusted EBITDA; the Company's expected leverage; the Company's ability to repeat its M\&A strategy; the expected growth and market position of the Company's core brands; the Company's brand-building and product development initiatives; and the Company's ability to create long-term value. Words such as "trend," "continue," " will," "expect," "project," "anticipate," "likely," ' estimate," "may," " should," "could," "would," and similar expressions identify forward-looking statements. Such forward-looking statements represent the Company's expectations and beliefs and involve a number of known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include, among others, general economic and business conditions, competitive pressures, the impact of the Company's product development and brand-building initiatives, difficulties successfully integrating the Fleet brands, manufacturing facility and R\&D resources, supplier issues, and other risks set forth in Part I, Item 1A. Risk Factors in the Company's Annual Report on Form 10-K for the year ended March 31, 2016 and in Part II, Item 1A. Risk Factors in the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2016. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation. Except to the extent required by applicable law, the Company undertakes no obligation to update any forward-looking statement contained in this presentation, whether as a result of new information, future events, or otherwise.

All adjusted GAAP numbers presented are footnoted and reconciled to their closest GAAP measurement in the attached reconciliation schedule or in our earnings release in the "About Non-GAAP Financial Measures" section.

## Agenda for Today's Discussion

I. Performance Highlights
II. FY 17 Year in Review
III. Financial Oueruiew
IV. FY 18 Outlook

## I. Performance Highlights



## 24 FY 17 Performance Highlights

- Q4 Revenue of $\$ \mathbf{2 4 0 . 7}$ million, up $\mathbf{1 5 . 8 \%}$ versus PY Q4


## Demonstrated Portfolio Growth

Strong
Earnings
and FCF

MéA

- Organic revenue growth of $1.1 \%^{(1)}$
- Revenue growth of $1.9 \%^{(1)}$ for Invest for Growth* portfolio
- Strong consumption gains at Care Pharma, which resulted in sales growth of $+11.5 \%$
- Consistent gross margin for legacy business
- Adjusted EPS of $\$ 0.54^{(2)}$, up $3.8 \%$ versus PY Q4
- Continued solid Adjusted Free Cash Flow of $\$ 46.8$ million ${ }^{(2)}$, resulting in a leverage of $5.7 \mathrm{x}^{(3)}$
- Completed the acquisition of C.B. Fleet on January $26^{\text {th }}, 2017$
- Significant integration activity achieved and on plan to be largely completed by the end of Q1 FY 18
- FY 18 priorities include brand building and supply chain integration

[^0]
## Strong Financial Performance in FY 17

Revenue of \$882 million, up 9.4\% versus FY 16

Organic Revenue growth of $+1.0 \%^{(1)}$ and $+2.8 \%^{(1)}$ for Invest For Growth portfolio

Adjusted EPS of \$2.37 ${ }^{(2)}$, up 9.2\% versus FY 16

Adjusted Free Cash Flow of \$196 million ${ }^{(2)}$, up 6.9\% versus FY 16

Free cash flow generation and brand divestitures of over $\$ 300$ million, used primarily for debt reduction and funding MéA

## II. FY 17 Year in Review

CompoundW Fleet. Summers Eve Dramamine Dentak LUDEN'S.
LITTLE
REMEDIES
Efferdent
Clear
eyes.
(3C) Goodys
Chloraseptic Nix

## Continuing to Deliver Against Strategy

(1) Target Portfolio Configuration Milestone Achieved

## 2 Sustained Brand-Building Investment Deployed for Long-Term Growth

## 3 <br> Proven and Repeatable méA Strategy

4
Consistent and Increasing Free Cash Flow

## Target Portfolio Mix Milestone Achieved



## Significant Portfolio Euolution Ouer the Past Fiscal Year



December 2016
Dermoplast


Core Brands Gaining Share in Their Categories


[^1]
## New Product Development Is A Key Part of Our Brand-Building Strategy

Recent new products introduced across our portfolio

|  | GI |  | Analgesics | Eye e Ear Care | Dermatologicals | Care |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Dramamine <br>  Dramamine $\qquad$ |  | $\mathrm{TV}_{\text {REMLE }}$ |  |  |  |  |

- Consumer research and shopper insights identify unmet needs
- Match new product opportunities to each brand's unique positioning
- Goal to launch 3 to 5 meaningful new product innovations annually


## New Product Development Contributing to Growth

|  | Clear <br> eyes. | Goodly: | Dramamine |  | Compound Wh. | LITTLE REMEDIES |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Product Development Initiatives |  |  | $\frac{\mathrm{Z}=}{\frac{\text { Diamane }}{\text { Den }}}$ |  |  |  |
| Extend Brand Through Better Consumer Experience or Claims | $\sqrt{ }$ | $\sqrt{ }$ | $\sqrt{ }$ | $V$ | $\sqrt{ }$ | $\sqrt{ }$ |
| Innovate Through Technology |  |  |  | $\sqrt{V}$ | $\sqrt{ }$ |  |
| Expand Brand in New Channels |  | C-Stores | On-the-Go |  |  | e-Commerce |

## Integration and Synergy Sauings On Track

## Milestones



- "Order-to-cash" integrated sales platform complete
- Cross sharing of international resources begins
- Closed Fleet's New Jersey executive office
- Consolidated support into PBH structure; exits completed by Q1 FY 18
- Warehouse and freight consolidated into existing footprint
- Fleet R\&D lab expanding to new brands
- Launched "Simply" Summer's Eve line, additional NPD identified
- Integrated Women's Health sales efforts

Strategy Has Delivered Consistently Strong Financial Performance


## Strong and Consistent Cash Flow Leads to Rapid De-Levering



## III. Financial Ouerview

| Compour | Flee | SummersEve | Dra | Dentar LUDENS. |
| :---: | :---: | :---: | :---: | :---: |
|  | Efferdent | Clear | (30) Goocts | Chloreperic Nix |
| beaño | Hydraye | MONISAT | T Goustom | brer |

## Key Financial Results for Fourth 2uarter e FY 17 Performance

- Solid overall financial performance in Q4 and FY 17
- Q4 Revenue of $\$ 240.7$ million, an increase of $15.8 \%$
- FY 17 Adjusted EBITDA ${ }^{(2)}$ of $\$ 304.5$ million
- Q4 Adjusted EPS of $\$ 0.54^{(2)}$, up $3.8 \%$ vs prior year, and FY 17 Adjusted EPS of $\$ 2.37^{(2)}$, up $9.2 \%$
- Transitional quarter with C.B. Fleet integration, which contributed $\$ 38.7$ million in Revenue and was $\$ 0.01$ dilutive to EPS in Q4



## FY 17 Fourth Quarter Consolidated Financial Summary

|  | 3 Months Ended |  |  |  |  | 12 Months Ended |  |  |  |  | 24 Commentary |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q4 FY 17 |  | Q4 FY 16 |  | \% Chg | FY 17 |  | FY 16 |  | \% Chg | - Revenue growth of $+15.8 \%$ |
| Total Revenue | \$ | 240.7 | \$ | 207.9 | 15.8\% | \$ | 882.1 | \$ | 806.2 | 9.4\% | - Organic growth of $1.1 \%{ }^{(1)}$ |
| Adjusted Gross Profit ${ }^{(2)^{*}}$ \% Adjusted Margin |  | $\begin{aligned} & 133.2 \\ & 55.4 \% \end{aligned}$ |  | $\begin{gathered} 119.6 \\ 57.6 \% \end{gathered}$ | 11.3\% |  | $\begin{gathered} 503.3 \\ 57.1 \% \end{gathered}$ |  | $\begin{gathered} 468.6 \\ 58.1 \% \end{gathered}$ | 7.4\% | - Fleet contributed \$38.7 |
| Adjusted A\&P ${ }^{(2)}$ \% Total Revenue |  | $\begin{array}{r} 39.2 \\ 16.3 \% \end{array}$ |  | $\begin{array}{r} 26.6 \\ 12.8 \% \end{array}$ | 47.7\% |  | $\begin{gathered} 126.1 \\ 14.3 \% \end{gathered}$ |  | $\begin{aligned} & 110.8 \\ & 13.7 \% \end{aligned}$ | 13.8\% | million of revenue <br> - Adjusted Gross Margin of $55.4 \%$ |
| Adjusted G\&A ${ }^{(2)}$ \% Total Revenue |  | $\begin{aligned} & 19.6 \\ & 8.1 \% \end{aligned}$ |  | $\begin{aligned} & 18.8 \\ & 9.1 \% \end{aligned}$ | 3.9\% |  | $\begin{gathered} 7.1 \\ 8.3 \% \end{gathered}$ |  | $\begin{gathered} 68.6 \\ 8.5 \% \end{gathered}$ | 6.6\% | - Adjusted A\&P 16.3\% of Revenue, or $\$ 39.2$ million |
| Adjusted EBITDA ${ }^{(2)}$ \% Margin | \$ | $\frac{74.9}{31.1 \%}$ | \$ | $\begin{array}{r} 74.2 \\ \hline 35.7 \% \end{array}$ | 0.9\% | \$ | $\begin{array}{r} 304.5 \\ \hline 34.5 \% \end{array}$ | \$ | 289.2 | 5.3\% | - Adjusted EBITDA Margin of |
| Adjusted Net Income ${ }^{(2)}$ | \$ | 28.8 | \$ | 27.9 | 3.2\% | \$ | 126.6 | \$ | 115.5 | 9.6\% | 31.1\% ${ }^{2}$ |
| Adjusted Earnings Per Share ${ }^{(2)}$ | \$ | 0.54 | \$ | 0.52 | 3.8\% | \$ | 2.37 | \$ | 2.17 | 9.2\% | - Adjusted Net Income +3.2\% ${ }^{(2)}$ over Q4 FY 16 |
|  |  |  |  |  |  |  |  |  |  |  | - Fleet contributed \$0.01 loss due to transitional quarter |

Industry Leading Free Cash Flow Trends


## IV. FY 18 Outlook

Compouncilw Fleet Sunmers Eve Dramamine Dentak LUDENS.

|  | Efferdent | Ciear | (BC) Goodts | Chlorsepic | Nix |
| :---: | :---: | :---: | :---: | :---: | :---: |
| beaño | Hydrance |  | AT Gow |  |  |

## FY 18 Full Year Outlook:

## Staying the Strategic Course to Continue Shareholder Value Creation

Top Line Trends

## Revenue

## Adjusted EPS ${ }^{(4)}$

Adjusted
Free Cash Flow ${ }^{(5)}$

- Strong momentum in our largest brands and international business going into FY 18
- Expect core OTC to outperform category growth
- Headwinds continue at retail, while Prestiges portfolio of need-based brands continues to be well positioned for future long-term growth
- Revenue growth of $+18 \%$ to $+20 \%$ ( $\$ 1,040$ to $\$ 1,060$ million)
- Organic growth of $+2.0 \%$ to $+2.5 \%$
- Adjusted EPS +9\% to $\mathbf{+ 1 3 \%}$ (\$2.58 to $\$ 2.68$ )
- Adjusted Free Cash Flow of \$205 million or more


## Long-Term Value Creation Strategy

## Expectation for Future



Long-Term E.P.S. Growth
Proven and Repeatable MéA Strategy

Upside Potential

## Long-Term Value Creation Strategy



## Appendix

(1) Organic Revenue Growth is a Non-GAAP financial measure and is reconciled to its most closely related GAAP financial measure in our earnings release in the "About Non-GAAP Financial Measures" section.
(2) Adjusted Gross Margin, Adjusted A\&P, Adjusted G\&A, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjusted EPS, Adjusted Free Cash Flow are Non-GAAP financial measures and are reconciled to their most closely related GAAP financial measures in the attached Reconciliation Schedules and / or in our earnings release in the "About Non-GAAP Financial Measures" section.
(3) Leverage ratio reflects net debt / covenant defined EBITDA.
(4) Adjusted EPS for FY 18 is a projected Non-GAAP financial measure, is reconciled to projected GAAP EPS in our earnings release in the "About Non-GAAP Financial Measures" section and is calculated based on projected GAAP EPS of $\$ 2.50$ to $\$ 2.60$ plus $\$ 0.08$ of costs associated with Fleet integration, resulting in \$2.58 to \$2.68.
(5) Adjusted Free Cash Flow for FY 18 is a projected Non-GAAP financial measure, is reconciled to projected GAAP Net Cash Provided by Operating Activities in our earnings release in the "About Non-GAAP Financial Measures" section and is calculated based on projected Net Cash Provided by Operating Activities of $\$ 210$ million less projected capital expenditures of $\$ 10$ million plus payments associated with acquisitions of $\$ 8$ million less tax effect of payments associated with acquisitions of $\$ 3$ million

## Reconciliation Schedules

## Organic Revenue Growth

|  | Three Months Ended Mar. 31, |  |  |  | Twelve Months Ended March. 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| GAAP Total Revenues | \$ | 240,670 | \$ | 207,855 | \$ | 882,060 | \$ | 806,247 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Revenues associated with acquisitions |  | $(43,125)$ |  | - |  | $(94.293)$ |  | - |
| Revenues associated with divested brands |  | - |  | $(12,460)$ |  | - |  | $(26,002)$ |
| Total adjustments |  | (43,125) |  | (12,460) |  | $(94,293)$ |  | (26,002) |
| Non-GAAP Organic Revenues | \$ | 197,545 | \$ | 195,395 | \$ | 787,767 | \$ | 780,245 |
| Organic Revenue Growth |  | 1.1\% |  |  |  | 1.0\% |  |  |

## Reconciliation Schedules Cont’d

## Adjusted GéA

|  | Three Months Ended Mar. 31, |  |  |  | Twelve Months Ended March. 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| GAAP General and Administrative Expense | \$ | 28,760 | \$ | 20,232 | \$ | 89,143 | \$ | 72,418 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Costs Associated with CEO transition |  | - |  | - |  | - |  | 1,406 |
| Legal and professional fees associated with acquisitions and divestitures |  | 3.431 |  | 1.096 |  | 6,560 |  | 2.112 |
| Integration, transition and other costs associated withacquisitions and divestitures |  | 5.756 |  | 289 |  | 9.455 |  | 289 |
| Total adjustments |  | 9.187 |  | 1,385 |  | 16,015 |  | 3,807 |
| Non-GAAP Adjusted General and Administrative Expense | \$ | 19,573 | \$ | 18,847 | \$ | 73,128 | \$ | 68,611 |
| Non-GAAP Adjusted General and Administrative ExpensePercentage |  | 8.1\% |  | 9.1\% |  | 8.3\% |  | 8.5\% |

[^2]
## Reconciliation Schedules Cont’d

## Adjusted EBITDA

|  | Three Months Ended Mar. 31, |  |  |  | Twelve Months Ended March. 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| GAAP Net (Loss) Income | \$ | 11,090 | \$ | 13,936 | \$ | 69,395 | \$ | 99,907 |
| Interest expense, net |  | 32,832 |  | 23,147 |  | 93,343 |  | 85,160 |
| (Benefit) provision for income taxes |  | 7.712 |  | 10,667 |  | 41.455 |  | 57.278 |
| Depreciation and amortization |  | 7.092 |  | 6,198 |  | 25,792 |  | 23.676 |
| Non-GAAP EBITDA |  | 58,726 |  | 53,948 |  | 229,985 |  | 266,021 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Inventory step-up charges associated with acquisitions |  | 1,664 |  | 1,387 |  | 1,664 |  | 1,387 |
| Costs associated with CEO transitions |  | - |  | - |  | - |  | 1,406 |
| Legal and professional fees associated with acquisitions and divestitures |  | 3.431 |  | 1.096 |  | 6.560 |  | 2.112 |
| Integration, transition and other costs associated with acquisitions and divestitures |  | 9,365 |  | 289 |  | 13,064 |  | 289 |
| Loss on extinguishment of debt |  | 1,420 |  | 17,519 |  | 1,420 |  | 17,970 |
| (Gain) loss on divestitures |  | 268 |  | - |  | 51,820 |  | - |
| Total adjustments |  | 16,148 |  | 20,291 |  | 74,528 |  | 23,164 |
| Non-GAAP Adjusted EBITDA | \$ | 74,874 | \$ | 74,239 | \$ | 304,513 | \$ | 289,185 |
| Non-GAAP Adjusted EBITDA Margin |  | 31.1\% |  | 35.7\% |  | 34.5\% |  | 35.9\% |

## Reconciliation Schedules Cont’d

## Adjusted EBITDA

| Adjusted EBITDA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2011 |  | 2012 |  | 2013 |  | 2014 |  | 2015 |  | 2016 |  | 2017 |  |
| GAAP Net Income | \$ | 29,220 | \$ | 37,212 | \$ | 65,505 | \$ | 72.615 | \$ | 78,260 | \$ | 99,907 | \$ | 69,395 |
| Income from Disc Ops |  | (591) |  | - |  | - |  | - |  | - |  | - |  | - |
| Loss on sale of disc ops |  | 550 |  | - |  | - |  | - |  | - |  | - |  | - |
| Interest Expense, net |  | 27,317 |  | 41,320 |  | 84,407 |  | 68.582 |  | 81,234 |  | 85,160 |  | 93.343 |
| Provision for income taxes |  | 19,349 |  | 23,945 |  | 40,529 |  | 29.133 |  | 49,198 |  | 57,278 |  | 41,455 |
| Depreciation and amortization |  | 9,876 |  | 10,734 |  | 13,235 |  | 13,486 |  | 17,740 |  | 23,676 |  | 25,792 |
| Non-GAAP EBITDA |  | 85,721 |  | 113,211 |  | 203,676 |  | 183,816 |  | 226,432 |  | 266,021 |  | 229,985 |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Sales costs related to acquisitions |  | - |  | - |  | 411 |  | - |  | - |  | - |  | - |
| Inventory step up |  | 7,273 |  | 1,795 |  | 23 |  | 577 |  | 2.225 |  | 1,387 |  | 1,664 |
| Inventory related acquisition costs |  | - |  | - |  | 220 |  | 407 |  | - |  | - |  | - |
| Add'l supplier costs |  | - |  | - |  | 5,426 |  | - |  | - |  | - |  | - |
| Costs associated with CEO transition |  | - |  | - |  | - |  | - |  | - |  | 1,406 |  |  |
| Legal and other professional fees associated with acquisitions |  | 7,729 |  | 13,807 |  | 98 |  | 1,111 |  | 10,974 |  | 2.112 |  | 6.560 |
| Integration, transition, and other Acq costs |  | - |  | 3,588 |  | 5.811 |  | - |  | 10,533 |  | 289 |  | 13,064 |
| Stamp Duty |  | - |  | - |  | - |  | - |  | 2,940 |  | - |  | - |
| Unsolicited porposal costs |  | - |  | 1,737 |  | 534 |  | - |  | - |  | - |  | - |
| Loss on extinguishment of debt |  | 300 |  | 5,409 |  | 1,443 |  | 18.286 |  | - |  | 17,970 |  | 1,420 |
| Gain on settlement |  | - |  | $(5.063)$ |  | - |  | - |  | - |  | - |  | - |
| Gain on sale of asset |  | - |  | - |  | - |  | - |  | $(1,133)$ |  | - |  | 51,820 |
| Adjustments to EBITDA |  | 15,302 |  | 21,273 |  | 13,966 |  | 20,381 |  | 25,539 |  | 23,164 |  | 74,528 |
| Non-GAAP Adjusted EBITDA | \$ | 101,023 | \$ | 134,484 | \$ | 217,642 | \$ | 204,197 | \$ | 251,971 | \$ | 289,185 | \$ | 304,513 |

[^3]
## Reconciliation Schedules Cont’d

## Adjusted Net Income and Adjusted EPS

## GAAP Net Income

Adjustments
Inventory step-up charges and other costs associate with acquisitions
Costs associated with CEO transition
Legal and professional fees associated with acquisitions and divestitures
Integration, transition and other costs associated with acquisitions and divestitures
Accelerated amortization of debt orgination costs
Additional interest expense from Term Loan B-4 debt refinancing
Loss on extinguishment of debt
(Gain) loss on divestitures
Tax impact of adjustments
Tax impacts related to tax reserve adjustments
Total Adjustments
Non-GAAP Adjusted Net Income and Adjusted EPS


[^4]
## Reconciliation Schedules Cont’d

## Adjusted Net Income and Adjusted EPS

|  | 2011 |  | 2012 |  | 2013 |  | 2014 |  | 2015 |  | 2016 |  | 2017 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Net Income | EPS | Net Income | EPS | $\begin{gathered} \text { Net } \\ \text { Income } \end{gathered}$ | EPS | Net Income | EPS | Net Income | EPS | Net Income | EPS | Net Income | EPS |
| GAAP Net Income | \$29,220 | \$0.58 | \$ 37,212 | \$ 0.73 | \$65,505 | \$ 1.27 | \$ 72,615 | \$ 1.39 | \$78,260 | \$ 1.49 | \$99,907 | \$ 1.88 | \$ 69,395 | \$ 1.30 |
| Adjustments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Income from discontinued ops. | (591) | (0.01) | - | - | - | - | - | - | - | - | - | - | - | - |
| Loss on sale of discontinued ops. | 550 | 0.01 | - | - | - | - | - | - | - | - | - | - | - | - |
| Incremental interest expense to finance Acquisition | 800 | 0.02 | - | - | - | - | - | - | - | - | - | - | 9,184 | 0.17 |
| Sales costs related to acquisitions | - | - | - | - | 411 | 0.01 | - | - | - | - | - | - | - | - |
| Inventory step up | 7.273 | 0.14 | 1.795 | 0.04 | 23 | - | 577 | 0.01 | 2.225 | 0.04 | 1,387 | 0.03 | 1,664 | 0.03 |
| Inventory related acquisition costs | - | - | - | - | 220 | - | 407 | 0.01 | - | - | - | - | - | - |
| Add'l supplier costs | - | - | - | - | 5.426 | 0.11 | - | - | - | - | - | - | - | - |
| Costs associated with CEO transition | - | - | - | - | - | - | - | - | - | - | 1.406 | 0.02 | - | - |
| Legal and other professional fees associated with acquisitions | 7.729 | 0.15 | 13.807 | 0.27 | 98 | - | 1,111 | 0.02 | 10,974 | 0.21 | 2.112 | 0.04 | 6,560 | 0.12 |
| Integration, Transition, and other Acq costs | - | - | 3.588 | 0.07 | 5.811 | 0.11 | - | - | 10.533 | 0.20 | 289 | 0.01 | 13.064 | 0.24 |
| Stamp Duty | - | - | - | - | - | - | - | - | 2.940 | 0.05 | - | - | - | - |
| Unsolicited porposal costs | - | - | 1.737 | 0.03 | 534 | 0.01 | - | - | - | - | - | - | - | - |
| Loss on extinguishment of debt | 300 | 0.01 | 5,409 | 0.11 | 1.443 | 0.03 | 18,286 | 0.35 | - | - | 17.970 | 0.34 | 1,420 | 0.03 |
| Gain on settlement | - | - | $(5.063)$ | (0.10) | - | - | - | - | - | - | - | - | - | - |
| (Gain) loss on divestitures | - | - | - | - | - | - | - | - | - | - | - | - | 51,820 | 0.97 |
| (Gain) loss on sale of asset | - | - | - | - | - | - | - | - | (1.133) | (0.02) | - | - | - | - |
| Accelerated amortization of debt discounts and debt issue costs | - | - | - | - | 7.746 | 0.15 | 5.477 | 0.10 | 218 | - | - | - | 1,706 | 0.03 |
| Tax impact on adjustments | (5.513) | (0.11) | (8.091) | (0.16) | $(8.329)$ | (0.16) | (9,100) | (0.17) | $(5,968)$ | (0.11) | $(7,608)$ | (0.15) | (28.024) | (0.52) |
| Impact of state tax adjustments | - | - | (237) | - | (1,741) | (0.03) | (9.465) | (0.18) | - | - | - | - | (199) | - |
| Total adjustments | 10,548 | 0.21 | 18,008 | 0.36 | 11,642 | 0.23 | 7,293 | 0.14 | 19,789 | 0.37 | 15,556 | 0.29 | 57,195 | 1.07 |
| Non-GAAP Adjusted Net Income and Non-GAAP Adjusted EPS | \$39,768 | \$ 0.79 | \$55,220 | \$ 1.09 | \$ 77,147 | \$ 1.50 | \$79,908 | \$ 1.53 | \$98,049 | \$ 1.86 | \$115,463 | \$ 2.17 | \$126,590 | \$ 2.37 |

Dollar values in thousands.

## Reconciliation Schedules Cont'd

## Adjusted Free Cash Flow

|  | Three Months Ended Mar. 31, |  |  |  | Twelve Months Ended March. 31, |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 2017 |  | 2016 |  | 2017 |  | 2016 |  |
| GAAP Net (Loss) Income | \$ | 11,090 | \$ | 13,936 | \$ | 69,395 | \$ | 99,907 |
| Adjustments: |  |  |  |  |  |  |  |  |
| Adjustments to reconcile net (loss) income to net cash provided by operating activities as shown in the Statement of Cash Flows |  | 21,347 |  | 34,206 |  | 91,713 |  | 96,221 |
| Changes in operating assets and liabilities, net of effects from acquisitions as shown in the Statement of Cash Flows |  | $(25,013)$ |  | $(10,243)$ |  | $(13,336)$ |  | $(21,778)$ |
| Total Adjustments |  | $(3,666)$ |  | 23,963 |  | 78,377 |  | 74,443 |
| GAAP Net cash provided by operating activities |  | 7,424 |  | 37,899 |  | 147,772 |  | 174,350 |
| Purchase of property and equipment |  | (1,042) |  | $(1,028)$ |  | $(2,977)$ |  | $(3,568)$ |
| Non-GAAP Free Cash Flow |  | 6,382 |  | 36,871 |  | 144,795 |  | 170,782 |
| Premium payment on extinguishment of 2012 Senior Notes |  | - |  | 10,158 |  | - |  | 10,158 |
| Integration, transition and other payments associated with acquisitions and divestitures |  | 8,304 |  | 1,665 |  | 10,448 |  | 2,461 |
| Additioanl interest on Term Loan B-4 debt refinancing |  | 9.184 |  | - |  | 9.184 |  | - |
| Pension contribution |  | 6,000 |  | - |  | 6.000 |  | - |
| Additional income tax payments associated with divestitures |  | 16,956 |  | - |  | 25,545 |  | - |
| Non-GAAP Adjusted Free Cash Flow | \$ | 46,826 | \$ | 48,694 | \$ | 195,972 | \$ | 183,401 |

## Reconciliation Schedules Cont’d

## Adjusted Free Cash Flow

|  | 2010 |  | 2011 |  | 2012 |  | 2013 |  | 2014 |  | 2015 |  | 2016 |  | 2017 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| GAAP Net Income | \$ | 32.115 | \$ | 29,220 | \$ | 37.212 | \$ | 65,505 | \$ | 72,615 | \$ | 78,260 | \$ | 99,907 | \$ | 69,395 |
| Adjustments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Adjustments to reconcile net income to net cash provided by operating activities as shown in the statement of cash flows |  | 31,137 |  | 26,095 |  | 35,674 |  | 59,497 |  | 50,912 |  | 64,668 |  | 96,221 |  | 91,713 |
| Changes in operating assets and liabilities, net of effects from acquisitions as shown in the statement of cash flows |  | $(3,825)$ |  | 31,355 |  | $(5,434)$ |  | 12,603 |  | $(11,945)$ |  | 13.327 |  | (21,778) |  | $(13,336)$ |
| Total adjustments |  | 27,312 |  | 57,450 |  | 30.240 |  | 72.100 |  | 38,967 |  | 77,995 |  | 74,443 |  | 78,377 |
| GAAP Net cash provided by operating activities |  | 59,427 |  | 86,670 |  | 67,452 |  | 137,605 |  | 111,582 |  | 156,255 |  | 174,350 |  | 147,772 |
| Purchases of property and equipment |  | (673) |  | (655) |  | (606) |  | $(10,268)$ |  | $(2,764)$ |  | $(6,101)$ |  | (3,568) |  | $(2,977)$ |
| Non-GAAP Free Cash Flow |  | 58,754 |  | 86,015 |  | 66,846 |  | 127,337 |  | 108,818 |  | 150,154 |  | 170,782 |  | 144,795 |
| Premiuim payment on 2010 Senior Notes |  | - |  | - |  | - |  | - |  | 15,527 |  | - |  | - |  | - |
| Premiuim payment on extinguishment of 2012 Senior Notes |  | - |  | - |  | - |  | - |  | - |  | - |  | 10,158 |  | - |
| Accelerated interest payments due to debt refinancing |  | - |  | - |  | - |  | - |  | 4.675 |  | - |  | - |  | 9.184 |
| Integration, transition and other payments associated with acquisitions |  | - |  | - |  | - |  | - |  | 512 |  | 13,563 |  | 2,461 |  | 10,448 |
| Pension contribution |  |  |  | - |  | - |  | - |  | - |  | - |  | - |  | 6,000 |
| Additional income tax payments associated with divestitures |  |  |  | - |  | - |  | - |  | - |  | - |  | - |  | 25,545 |
| Total adjustments |  | - |  | - |  | - |  | - |  | 20,714 |  | 13.563 |  | 12,619 |  | 51,177 |
| Non-GAAP Adjusted Free Cash Flow | \$ | 58,754 | \$ | 86,015 | \$ | 66,846 | \$ | 127,337 | \$ | 129,532 | \$ | 163,717 | \$ | 183,401 | \$ | 195,972 |

[^5]
## Reconciliation Schedules Cont’d

## Projected EPS

## Projected Free Cash Flow

|  | 2018 Projected EPS |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Low |  | High |  |
| Projected FY'18 GAAP EPS | \$ | 2.50 | \$ | 2.60 |
| Adjustments: |  |  |  |  |
| Costs associated with Fleet integration ${ }^{(1)}$ |  | 0.08 |  | 0.08 |
| Total Adjustments |  | 0.08 |  | 0.08 |
| Projected Non-GAAP Adjusted EPS | \$ | 2.58 | \$ | 2.68 |


|  | 2018 Projected <br> Free Cash Flow |  |
| :--- | ---: | ---: |
|  | $\$$ | 210 |
| Projected FY'18 GAAP Net Cash provided by operating activities | $(10)$ |  |
| Additions to property and equipment for cash | 200 |  |
| Projected Non-GAAP Free Cash Flow | 8 |  |
| Payments associated with acquisitions | $(3)$ |  |
| Tax effect of payments associated with aqquisitions | 205 |  |
| Adjusted Non-GAAP Projected Free Cash Flow |  |  |

(1) Acquisition related items represent costs related to integrating recently acquired businesses including (but not limited to), warehouse consolidation, costs to exit or convert contractual obligations, severance, information system conversion and consulting costs and certain costs related to the consummation of the acquisition process such as legal and other acquisition related professional fees.


[^0]:    * Invest for Growth portfolio comprised of Core OTC brands and International. Core OTC brands reflect, Monistat. BC/Goody's, Clear Eyes. DenTek. Dramamine. Debrox, Chloraseptic, Luden's, Little Remedies, Compound W. Nix, Beano, Efferdent and The Doctor's IRI multi-outlet + C-Store retail dollar sales for relevant period. International includes Canadian consumption for leading retailers, and Australia/ROW shipment data as a proxy for consumption.

[^1]:    Source: IRI multi-outlet + C-Store retail dollar sales for the period ending 03/29/2017

[^2]:    Dollar values in thousands.

[^3]:    Dolar values in thousands.

[^4]:    Dolar values in thousands.

[^5]:    Dollar values in thousands. except per share data.

